Abiopharma

New Form 10-Q - BIOXYTRAN, INC Filed: 2025-08-11 AccNo: 0001493152-25-011797 Size: 7 MB

New Form 8-K - HARVARD BIOSCIENCE INC Filed: 2025-08-11 AccNo: 0001171843-25-005262 Size: 376 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 10-Q - Compass Therapeutics, Inc. Filed: 2025-08-11 AccNo: 0001171843-25-005261 Size: 5 MB

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

BioCryst Announces Departure of Dr. Helen Thackray

KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights

New Form 8-K - Energous Corp Filed: 2025-08-11 AccNo: 0001104659-25-075898 Size: 280 KB Item 3.03: Material Modifications to Rights of Security Holders Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 6-K - KAMADA LTD Filed: 2025-08-11 AccNo: 0001213900-25-073908 Size: 27 KB

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

New Form 8-K - Stoke Therapeutics, Inc. Filed: 2025-08-11 AccNo: 0001193125-25-177433 Size: 174 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2